top of page
News
Search
Renovion Announces Positive Top-Line Results from Phase 2 CLIMB Study of ARINA-1 (RVN-301) in Patients with Non-Cystic Fibrosis Bronchiectasis
Elevated QOL in NCFBE patients with ARINA-1 treatment. Robust data show significant symptom improvement surpassing clinical thresholds.
Renovion
Apr 30, 20245 min read
Renovion Provides Regulatory Update and Initiation of Clinical Program in Non-CF Bronchiectasis
Renovion, Inc., a clinical-stage pharmaceutical company focused on developing treatments for rare, chronic, and serious lung diseases...
Renovion
Apr 7, 20222 min read
bottom of page